CONTACT GSK 1-877-512-1344
Listen to Dr. David Lipson discuss IMPACT, a landmark clinical trial of TRELEGY vs an ICS/LABA (FF/VI) and vs a LAMA/LABA (UMEC/VI).
CI=confidence interval; COPD=chronic obstructive pulmonary disease; CYP3A4=cytochrome P450 3A4; ECG= electrocardiogram; FEV1=forced expiratory volume in 1 second; FF=fluticasone furoate; GOLD=Global Initiative for Chronic Obstructive Lung Disease; ICS=inhaled corticosteroid; IMPACT=InforMing the PAthway of COPD Treatment; LABA=long-acting beta2-agonist; LAMA=long-acting muscarinic antagonist; LS=least squares; NS=not significant; UMEC=umeclidinium; VI=vilanterol
References: 1. Lipson DA, Barnhart F, Brealey N, et al; for the IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-1680. 2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2018 report. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed October 30, 2018. 3. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138. 4. Müllerova H, Gelhorn H, Wilson H, et al. St George’s Respiratory Questionnaire score predicts outcomes in patients with COPD: analysis of individual patient data in the COPD Biomarkers Qualification Consortium Database. Chronic Obstr Pulm Dis. 2017;4(2):141-149. 5. Mapel DW, Roberts MH. New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. Pharmacoeconomics. 2012;30(10):869-885. 6. Data on file, GSK.
Your patients may come to you with questions about TRELEGY — we encourage you to watch this commercial.
Stay up-to-date with new information on